Table 3 Input parameters of costs, ¥
Parameters | Value | Range | Source |
|---|---|---|---|
Average Acquisition price of drugs, mg | |||
 Bortezomib | 349 | 279—419 | Collected by authors |
 Carfilzomib | 98 | 78—118 | Collected by authors |
 Ixazomib | 1,319 | 1,055—1,583 | Collected by authors |
 Lenalidomide | 2.0 | 1.8—2.2 | Collected by authors |
 Pomalidomide | 66 | 53—79 | Collected by authors |
 Daratumumab | 20 | 16—24 | Collected by authors |
 Selinexor | 59 | 47—71 | Collected by authors |
Assumed price of drugs based on listed price in US market, mg | |||
 Panobinostat | 1,599 | 1,279—1,919 | [38] |
 Elotuzumab | 54 | 43—65 | [38] |
 Isatuximab | 58 | 46—70 | [38] |
IV administration | 6 | 5—7 | Collected by authors |
SC administration | 3 | 2—4 | Collected by authors |
Costs for AEs (grade ≥ 3) management | |||
 Neutropenia | 36,465 | 29,172—43,758 | Collected by authors |
 Anemia | 20,780 | 16,624—24,936 | Collected by authors |
 Thrombocytopenia | 20,136 | 16,109—24,163 | Collected by authors |
 Pneumonia | 14,983 | 11,986—17,980 | Collected by authors |
Follow-up costs, monthly | |||
 First year | 1,186 | 949—1423 | Collected by authors |
 Second and third year | 593 | 474—712 | Collected by authors |
 Fourth and fifth year | 297 | 238—356 | Collected by authors |
Subsequent treatment costs, monthly | |||
 Bortezomib group | 35,857 | 23,722—35,584 | Collected by authors |
 Lenalidomide group | 32,755 | 28,686—43,028 | Collected by authors |
 Carfilzomib group | 29,653 | 26,204—39,306 | Collected by authors |
Last treatment costs, monthly | 39,048 | 31,238—46,858 | Collected by authors |
Hospice, monthly | 21,424 | 17,139—25,709 | [40] |